View ValuationSciDev 将来の成長Future 基準チェック /36SciDev収益と収益がそれぞれ年間106.7%と6.2%増加すると予測されています。主要情報106.7%収益成長率n/aEPS成長率Chemicals 収益成長42.6%収益成長率6.2%将来の株主資本利益率4.01%アナリストカバレッジLow最終更新日20 Apr 2026今後の成長に関する最新情報お知らせ • Feb 26SciDev Limited Revises Earnings Guidance for the Year 2026SciDev Limited revised earnings guidance for the year 2026. For the year, the company's FY26 Revenue guidance revised to $100 million - $110 million, reflecting: Recently confirmed delay in sales opportunity for xSlik® pushed into FY27. Delays to trial conversions in Process Chemistry confirmed in February. $3 million negative impact from higher AUD:USD on forecast USD revenue.すべての更新を表示Recent updatesお知らせ • Feb 26SciDev Limited Revises Earnings Guidance for the Year 2026SciDev Limited revised earnings guidance for the year 2026. For the year, the company's FY26 Revenue guidance revised to $100 million - $110 million, reflecting: Recently confirmed delay in sales opportunity for xSlik® pushed into FY27. Delays to trial conversions in Process Chemistry confirmed in February. $3 million negative impact from higher AUD:USD on forecast USD revenue.お知らせ • Feb 23SciDev Limited to Report First Half, 2026 Results on Feb 26, 2026SciDev Limited announced that they will report first half, 2026 results on Feb 26, 2026お知らせ • Sep 17SciDev Limited, Annual General Meeting, Nov 20, 2025SciDev Limited, Annual General Meeting, Nov 20, 2025.お知らせ • Aug 25SciDev Limited to Report Fiscal Year 2025 Results on Aug 27, 2025SciDev Limited announced that they will report fiscal year 2025 results Pre-Market on Aug 27, 2025お知らせ • Nov 21SciDev Limited Announces Resignation of Simone Watt as DirectorAs foreshadowed at today's 2024 Annual General Meeting, SciDev Ltd. announced the resignation of Simone Watt as Director of the Company. Simone joined the SciDev Board in October of 2018. She has provided six years of steadfast support and valued insights that have played a major role in the extraordinary growth and success of the business over that time. Her deep knowledge of relevant industries and markets has been invaluable to the Board and senior leadership team.お知らせ • Sep 27SciDev Limited, Annual General Meeting, Nov 21, 2024SciDev Limited, Annual General Meeting, Nov 21, 2024.Reported Earnings • Aug 28Full year 2024 earnings released: EPS: AU$0.012 (vs AU$0.002 loss in FY 2023)Full year 2024 results: EPS: AU$0.012 (up from AU$0.002 loss in FY 2023). Revenue: AU$109.2m (up 22% from FY 2023). Net income: AU$2.18m (up AU$2.51m from FY 2023). Profit margin: 2.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.Reported Earnings • Mar 03First half 2024 earnings released: EPS: AU$0 (vs AU$0 in 1H 2023)First half 2024 results: EPS: AU$0 (in line with 1H 2023). Revenue: AU$50.3m (up 1.5% from 1H 2023). Net income: AU$57.0k (up 111% from 1H 2023). Profit margin: 0.1% (in line with 1H 2023). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.お知らせ • Sep 30SciDev Limited, Annual General Meeting, Nov 21, 2023SciDev Limited, Annual General Meeting, Nov 21, 2023. Agenda: To consider re-election of Directors.Reported Earnings • Aug 30Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.003 loss in FY 2022)Full year 2023 results: AU$0.002 loss per share (improved from AU$0.003 loss in FY 2022). Revenue: AU$89.9m (up 62% from FY 2022). Net loss: AU$339.0k (loss narrowed 45% from FY 2022). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.New Risk • Aug 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (6.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Market cap is less than US$100m (€31.5m market cap, or US$34.0m).Reported Earnings • Feb 23First half 2023 earnings released: EPS: AU$0 (vs AU$0.014 loss in 1H 2022)First half 2023 results: EPS: AU$0 (improved from AU$0.014 loss in 1H 2022). Revenue: AU$49.6m (up 105% from 1H 2022). Net income: AU$27.0k (up AU$2.33m from 1H 2022). Profit margin: 0.1% (up from net loss in 1H 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Nov 29Independent & Non-Executive Director recently bought €52k worth of stockOn the 25th of November, Dan O’Toole bought around 266k shares on-market at roughly €0.19 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €82k more in shares than they have sold in the last 12 months.Reported Earnings • Sep 02Full year 2022 earnings released: AU$0.003 loss per share (vs AU$0.023 profit in FY 2021)Full year 2022 results: AU$0.003 loss per share (down from AU$0.023 profit in FY 2021). Revenue: AU$56.2m (up 32% from FY 2021). Net loss: AU$616.0k (down 118% from profit in FY 2021). Over the next year, revenue is forecast to grow 21%, compared to a 2.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Reported Earnings • Feb 24First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.014 loss per share (down from AU$0.003 profit in 1H 2021). Revenue: AU$24.1m (up 32% from 1H 2021). Net loss: AU$2.30m (down AU$2.73m from profit in 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 35%, compared to a 6.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has increased by 86% per year, which means it is tracking significantly ahead of earnings growth.Executive Departure • Dec 06Interim Chief Financial Officer Geoff Stephenson has left the companyOn the 6th of December, Geoff Stephenson's tenure as Interim Chief Financial Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Geoff's name. A total of 2 executives have left over the last 12 months.Reported Earnings • Sep 03Full year 2021 earnings released: EPS AU$0.023 (vs AU$0.007 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$44.2m (up 145% from FY 2020). Net income: AU$3.45m (up AU$4.33m from FY 2020). Profit margin: 7.8% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 168% per year, which means it is well ahead of earnings.Board Change • Sep 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Non-Executive Director Simone Watt is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Executive Departure • Jul 13Non-Executive Chairman Trevor Jones has left the companyOn the 30th of June, Trevor Jones' tenure as Non-Executive Chairman ended after 13.5 years in the role. As of March 2021, Trevor still personally held 1.20m shares (€248k worth at the time). Trevor is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.25 years.Is New 90 Day High Low • Feb 18New 90-day low: €0.42The company is down 18% from its price of €0.51 on 19 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.39 per share.Reported Earnings • Feb 11First half 2021 earnings released: EPS AU$0.003 (vs AU$0.002 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$18.3m (up 200% from 1H 2020). Net income: AU$427.5k (up AU$618.7k from 1H 2020). Profit margin: 2.3% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 112% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Feb 10Revenue beats expectationsRevenue exceeded analyst estimates by 0.2%. Over the next year, revenue is forecast to grow 58%, compared to a 5.1% growth forecast for the Chemicals industry in Germany.Is New 90 Day High Low • Nov 14New 90-day high: €0.53The company is up 32% from its price of €0.40 on 14 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 7.0% over the same period.業績と収益の成長予測DB:INFA - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202811432516/30/20279313516/30/202687-202112/31/2025102-3-20N/A9/30/2025103-2-11N/A6/30/2025104-113N/A3/31/2025106146N/A12/31/2024109278N/A9/30/2024109267N/A6/30/2024109246N/A3/31/2024100125N/A12/31/202391003N/A9/30/202390004N/A6/30/202390015N/A3/31/202385004N/A12/31/2022811-12N/A9/30/2022680-20N/A6/30/202256-1-4-1N/A3/31/2022520-20N/A12/31/202148102N/A9/30/2021452-10N/A6/30/2021433-2-1N/A3/31/2021362-2-2N/A12/31/2020300-3-2N/A9/30/202024-1-2-1N/A6/30/202018-1-10N/A3/31/202013-1-2-2N/A12/31/20198-2-4-3N/A9/30/20195-2N/A-2N/A6/30/20193-2N/A-2N/A3/31/20193-1N/A-1N/A12/31/201821N/A-1N/A9/30/201821N/A-1N/A6/30/201821N/A-1N/A3/31/201820N/A-1N/A12/31/20172-1N/A-1N/A9/30/20172-1N/A0N/A6/30/20172-1N/A0N/A3/31/20172-1N/A0N/A12/31/20162-1N/A0N/A9/30/20161-1N/A0N/A6/30/201610N/A-1N/A3/31/20161-1N/A-1N/A12/31/20152-1N/A-1N/A9/30/20152-1N/A-1N/A6/30/20152-1N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: INFAは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 1.9% ) よりも高い成長率であると考えられます。収益対市場: INFA今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: INFA今後 3 年以内に収益を上げることが予想されます。収益対市場: INFAの収益 ( 6.2% ) German市場 ( 6.5% ) よりも低い成長が予測されています。高い収益成長: INFAの収益 ( 6.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: INFAの 自己資本利益率 は、3年後には低くなると予測されています ( 4 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/11 13:09終値2026/05/11 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SciDev Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Cameron BellCanaccord Genuitynull nullMacquarie ResearchStephen ScottTaylor Collison Limited
お知らせ • Feb 26SciDev Limited Revises Earnings Guidance for the Year 2026SciDev Limited revised earnings guidance for the year 2026. For the year, the company's FY26 Revenue guidance revised to $100 million - $110 million, reflecting: Recently confirmed delay in sales opportunity for xSlik® pushed into FY27. Delays to trial conversions in Process Chemistry confirmed in February. $3 million negative impact from higher AUD:USD on forecast USD revenue.
お知らせ • Feb 26SciDev Limited Revises Earnings Guidance for the Year 2026SciDev Limited revised earnings guidance for the year 2026. For the year, the company's FY26 Revenue guidance revised to $100 million - $110 million, reflecting: Recently confirmed delay in sales opportunity for xSlik® pushed into FY27. Delays to trial conversions in Process Chemistry confirmed in February. $3 million negative impact from higher AUD:USD on forecast USD revenue.
お知らせ • Feb 23SciDev Limited to Report First Half, 2026 Results on Feb 26, 2026SciDev Limited announced that they will report first half, 2026 results on Feb 26, 2026
お知らせ • Sep 17SciDev Limited, Annual General Meeting, Nov 20, 2025SciDev Limited, Annual General Meeting, Nov 20, 2025.
お知らせ • Aug 25SciDev Limited to Report Fiscal Year 2025 Results on Aug 27, 2025SciDev Limited announced that they will report fiscal year 2025 results Pre-Market on Aug 27, 2025
お知らせ • Nov 21SciDev Limited Announces Resignation of Simone Watt as DirectorAs foreshadowed at today's 2024 Annual General Meeting, SciDev Ltd. announced the resignation of Simone Watt as Director of the Company. Simone joined the SciDev Board in October of 2018. She has provided six years of steadfast support and valued insights that have played a major role in the extraordinary growth and success of the business over that time. Her deep knowledge of relevant industries and markets has been invaluable to the Board and senior leadership team.
お知らせ • Sep 27SciDev Limited, Annual General Meeting, Nov 21, 2024SciDev Limited, Annual General Meeting, Nov 21, 2024.
Reported Earnings • Aug 28Full year 2024 earnings released: EPS: AU$0.012 (vs AU$0.002 loss in FY 2023)Full year 2024 results: EPS: AU$0.012 (up from AU$0.002 loss in FY 2023). Revenue: AU$109.2m (up 22% from FY 2023). Net income: AU$2.18m (up AU$2.51m from FY 2023). Profit margin: 2.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.
Reported Earnings • Mar 03First half 2024 earnings released: EPS: AU$0 (vs AU$0 in 1H 2023)First half 2024 results: EPS: AU$0 (in line with 1H 2023). Revenue: AU$50.3m (up 1.5% from 1H 2023). Net income: AU$57.0k (up 111% from 1H 2023). Profit margin: 0.1% (in line with 1H 2023). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.
お知らせ • Sep 30SciDev Limited, Annual General Meeting, Nov 21, 2023SciDev Limited, Annual General Meeting, Nov 21, 2023. Agenda: To consider re-election of Directors.
Reported Earnings • Aug 30Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.003 loss in FY 2022)Full year 2023 results: AU$0.002 loss per share (improved from AU$0.003 loss in FY 2022). Revenue: AU$89.9m (up 62% from FY 2022). Net loss: AU$339.0k (loss narrowed 45% from FY 2022). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
New Risk • Aug 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (6.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.5% net profit margin). Market cap is less than US$100m (€31.5m market cap, or US$34.0m).
Reported Earnings • Feb 23First half 2023 earnings released: EPS: AU$0 (vs AU$0.014 loss in 1H 2022)First half 2023 results: EPS: AU$0 (improved from AU$0.014 loss in 1H 2022). Revenue: AU$49.6m (up 105% from 1H 2022). Net income: AU$27.0k (up AU$2.33m from 1H 2022). Profit margin: 0.1% (up from net loss in 1H 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Nov 29Independent & Non-Executive Director recently bought €52k worth of stockOn the 25th of November, Dan O’Toole bought around 266k shares on-market at roughly €0.19 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €82k more in shares than they have sold in the last 12 months.
Reported Earnings • Sep 02Full year 2022 earnings released: AU$0.003 loss per share (vs AU$0.023 profit in FY 2021)Full year 2022 results: AU$0.003 loss per share (down from AU$0.023 profit in FY 2021). Revenue: AU$56.2m (up 32% from FY 2021). Net loss: AU$616.0k (down 118% from profit in FY 2021). Over the next year, revenue is forecast to grow 21%, compared to a 2.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Reported Earnings • Feb 24First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.014 loss per share (down from AU$0.003 profit in 1H 2021). Revenue: AU$24.1m (up 32% from 1H 2021). Net loss: AU$2.30m (down AU$2.73m from profit in 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 35%, compared to a 6.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has increased by 86% per year, which means it is tracking significantly ahead of earnings growth.
Executive Departure • Dec 06Interim Chief Financial Officer Geoff Stephenson has left the companyOn the 6th of December, Geoff Stephenson's tenure as Interim Chief Financial Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Geoff's name. A total of 2 executives have left over the last 12 months.
Reported Earnings • Sep 03Full year 2021 earnings released: EPS AU$0.023 (vs AU$0.007 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$44.2m (up 145% from FY 2020). Net income: AU$3.45m (up AU$4.33m from FY 2020). Profit margin: 7.8% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 168% per year, which means it is well ahead of earnings.
Board Change • Sep 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Non-Executive Director Simone Watt is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Executive Departure • Jul 13Non-Executive Chairman Trevor Jones has left the companyOn the 30th of June, Trevor Jones' tenure as Non-Executive Chairman ended after 13.5 years in the role. As of March 2021, Trevor still personally held 1.20m shares (€248k worth at the time). Trevor is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.25 years.
Is New 90 Day High Low • Feb 18New 90-day low: €0.42The company is down 18% from its price of €0.51 on 19 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.39 per share.
Reported Earnings • Feb 11First half 2021 earnings released: EPS AU$0.003 (vs AU$0.002 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$18.3m (up 200% from 1H 2020). Net income: AU$427.5k (up AU$618.7k from 1H 2020). Profit margin: 2.3% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 112% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Feb 10Revenue beats expectationsRevenue exceeded analyst estimates by 0.2%. Over the next year, revenue is forecast to grow 58%, compared to a 5.1% growth forecast for the Chemicals industry in Germany.
Is New 90 Day High Low • Nov 14New 90-day high: €0.53The company is up 32% from its price of €0.40 on 14 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 7.0% over the same period.